Advanced Biomed Inc (ADVB)

Form DEF 14A - Other definitive proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Advanced Biomed to Implement 1-for-20 Reverse Stock Split to Meet Nasdaq Requirement

Advanced Biomed Inc. (NASDAQ:ADVB) said it will carry out a 1-for-20 reverse stock split of its issued and outstanding common shares, effective...

Advanced Biomed Inc. Announces 1 for 20 Share Consolidation

Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”...

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Form 8-K - Current report